XENPOZYME (olipudase alfa-rpcp)
METABOLIC DISEASE ENZYME REPLACEMENT - ASMD · NON-CNS MANIFESTATIONS OF ACID SPHINGOMYELINASE DEFICIENCY
Sanofi-Aventis U.S.
Drug class
Metabolic Disease Enzyme Replacement - ASMD
The therapeutic classification "Metabolic Disease Enzyme Replacement - ASMD" refers to a targeted category of enzyme replacement therapies specifically designed to treat acid sphingomyelinase deficiency (ASMD), historically categorized as Niemann-Pick disease types A, A/B, and B. Read more about Metabolic Disease Enzyme Replacement - ASMD
1 drugs in this class 1 manufacturers
Drugs in Metabolic Disease Enzyme Replacement - ASMD
Filter & compare in the drug finder →
Opens the drug finder with Metabolic Disease Enzyme Replacement - ASMD preselected. Add indication or manufacturer filters there.
The therapeutic classification "Metabolic Disease Enzyme Replacement - ASMD" refers to a targeted category of enzyme replacement therapies specifically designed to treat acid sphingomyelinase deficiency (ASMD), historically categorized as Niemann-Pick disease types A, A/B, and B.
Agents in this class—exemplified by recombinant human acid sphingomyelinase (olipudase alfa)—function by providing an exogenous source of the missing or defective lysosomal hydrolytic enzyme.
This enzymatic activity catabolizes accumulated sphingomyelin into ceramide and phosphocholine, thereby alleviating toxic lipid storage within peripheral tissues.
Clinically, these agents are indicated to treat the non-central nervous system manifestations of chronic ASMD in pediatric and adult patients, demonstrating reductions in hepatosplenomegaly and improvements in pulmonary function.
-
youtube.com
The therapeutic classification "Metabolic Disease Enzyme Replacement - ASMD" refers to a targeted category of enzyme replacement therapies specifically designed to treat acid sphingomyelinase deficiency (ASMD), historically categorized as Niemann-Pick disease types A, A/B, and B This enzymatic activity catabolizes accumulated sphingomyelin into ceramide and phosphocholine, thereby alleviating toxic lipid storage within peripheral tissues Clinically, these agents are indicated to treat the non-ce...
-
europa.eu
The therapeutic classification "Metabolic Disease Enzyme Replacement - ASMD" refers to a targeted category of enzyme replacement therapies specifically designed to treat acid sphingomyelinase deficiency (ASMD), historically categorized as Niemann-Pick disease types A, A/B, and B
-
fda.gov
The therapeutic classification "Metabolic Disease Enzyme Replacement - ASMD" refers to a targeted category of enzyme replacement therapies specifically designed to treat acid sphingomyelinase deficiency (ASMD), historically categorized as Niemann-Pick disease types A, A/B, and B. Agents in this class—exemplified by recombinant human acid sphingomyelinase (olipudase alfa)—function by providing an exogenous source of the missing or defective lysosomal hydrolytic enzyme
-
sanofi.com
The therapeutic classification "Metabolic Disease Enzyme Replacement - ASMD" refers to a targeted category of enzyme replacement therapies specifically designed to treat acid sphingomyelinase deficiency (ASMD), historically categorized as Niemann-Pick disease types A, A/B, and B. Agents in this class—exemplified by recombinant human acid sphingomyelinase (olipudase alfa)—function by providing an exogenous source of the missing or defective lysosomal hydrolytic enzyme
-
incitefulmed.com
The therapeutic classification "Metabolic Disease Enzyme Replacement - ASMD" refers to a targeted category of enzyme replacement therapies specifically designed to treat acid sphingomyelinase deficiency (ASMD), historically categorized as Niemann-Pick disease types A, A/B, and B. Agents in this class—exemplified by recombinant human acid sphingomyelinase (olipudase alfa)—function by providing an exogenous source of the missing or defective lysosomal hydrolytic enzyme This enzymatic activity cata...
-
nnpdf.org
This enzymatic activity catabolizes accumulated sphingomyelin into ceramide and phosphocholine, thereby alleviating toxic lipid storage within peripheral tissues Clinically, these agents are indicated to treat the non-central nervous system manifestations of chronic ASMD in pediatric and adult patients, demonstrating reductions in hepatosplenomegaly and improvements in pulmonary function
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.